Search

St. John's Wort

Fenbendazole

Fenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs, cats, rabbits and seals. … It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and

AT2220

GAA to the lysosome, where it can perform its normal function. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

Rivanicline

Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. … It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8.

UB-612

The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … In addition, the vaccine contains a proprietary peptide UBITh®1a for enhanced immunogenicity, five identified peptides with Th or CTL epitopes to improve peptide solubility, and aluminum phosphate adjuvant

Rolicyclidine

Because of its pharmacodynamic similarity to the drug phencyclidine (PCP), rolicyclidine was added to the Schedule I list of illegal drugs in the USA in the 1970s.

Beraprost

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Albinterferon Alfa-2B

The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

CX501

the oesophagus. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

LY2275796

LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.